Search

Recursion Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

3.23 -5.83

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.18

Massimo

3.45

Metriche Chiave

By Trading Economics

Entrata

-14M

-131M

Vendite

1.2M

7.7M

EPS

-0.25

Margine di Profitto

-1,708.018

Dipendenti

600

EBITDA

-10M

-113M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+101.04% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

259M

1.9B

Apertura precedente

9.06

Chiusura precedente

3.23

Notizie sul Sentiment di mercato

By Acuity

100%

0%

322 / 339 Classifica in Healthcare

Recursion Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 19:46 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, despite a slight pullback from earlier highs. No specific news was identified for the move.

10 set 2026, 23:16 UTC

No specific news was identified for Recursion Pharmaceuticals Inc. during after-market hours. The stock remained roughly flat since Thursday's close.

9 set 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading, following a notable peak earlier in the session with no specific news identified.

8 set 2026, 22:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading. The stock remains above its 20-day moving average and near the upper end of its one-month range.

4 set 2026, 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 set 2026, 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 set 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

1 set 2026, 20:09 UTC

Recursion Pharmaceuticals Inc. shares are lower, following broader market declines amid rising oil prices and increasing U.S. Treasury yields. No specific company news was identified.

31 ago 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment reflects recent comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

28 ago 2026, 23:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market hours, following three consecutive lower finishes. No specific news was identified to explain the movement.

27 ago 2026, 23:02 UTC

Recursion Pharmaceuticals Inc shares are trading higher in after-market hours. No specific news was identified to explain the price movement.

26 ago 2026, 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is declining amid a broader downturn in the Biotechnology sub-sector, with the ARK Genomic Revolution ETF also experiencing losses.

25 ago 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

24 ago 2026, 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21 ago 2026, 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20 ago 2026, 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19 ago 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18 ago 2026, 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17 ago 2026, 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12 ago 2026, 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 ago 2026, 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 ago 2026, 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 ago 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 ago 2026, 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 ago 2026, 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 ago 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 ago 2026, 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 lug 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 lug 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 lug 2026, 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

Confronto tra pari

Modifica del prezzo

Recursion Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

101.04% in crescita

Previsioni per 12 mesi

Media 6.433 USD  101.04%

Alto 8 USD

Basso 5.3 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Recursion Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

4 ratings

1

Acquista

3

Mantieni

0

Vendi

Sentiment

By Acuity

322 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat